Baxter International Inc.
BAX · NYSE
Company research
Baxter International Inc. (NYSE: BAX) is a global healthcare company founded in 1931 and headquartered in Deerfield, Illinois, that provides a broad portfolio of essential medical products and therapies to hospitals, dialysis centers, nursing homes, and home-based patients across approximately 100 countries. The company operates through three core segments — Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals — offering products ranging from sterile IV solutions, infusion systems, and parenteral nutrition therapies to dialysis treatments, inhaled anesthetics, generic injectable pharmaceuticals, and surgical hemostat and sealant products. Baxter also delivers connected care solutions, including smart bed systems, patient monitoring and diagnostic technologies, and advanced surgical equipment, through its Healthcare Systems & Technologies segment. Led by CEO Andrew Hider and employing approximately 38,000 full-time staff, the company reported revenues of approximately $10.6 billion in 2024 and distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies.
Research reports
StockStory · July 14, 2026Baxter (BAX) Research Report: Q1 CY2026 Update
StockStory rates Baxter as an underperformer, highlighting flat five‑year sales, declining EPS, negative ROIC and margin compression despite a modest revenue and EPS beat in Q1 2026, and argues that the stock’s low forward P/E mainly reflects weak business quality rather than mispricing.
MCH Advisory Services · July 7, 2026Baxter International Inc (BAX) — MCH Advisory ResearchMCH Advisory issues a SELL rating with a probability‑weighted equity value around 11–14% below spot, emphasizing thin free cash flow on roughly $8 billion of net debt, scenario analysis that assigns meaningful odds to reimbursement, competition and GLP‑1‑driven structural downside, and identifying gross margin as the single most important driver of valuation outcomes.
Yahoo Finance / Simply Wall St · June 14, 2026Baxter International (BAX) Stock Valuation Check After Recent Double Digit Gains And Ongoing Turnaround PlansThis article reassesses Baxter’s valuation after strong 30‑ and 90‑day share price gains but a still‑negative one‑year total return, comparing the current price to a fair‑value estimate only slightly higher and focusing on portfolio optimization, divestitures, cost cutting and elimination of stranded costs by 2027 as key elements of the turnaround thesis.
Beanvest · October 4, 2025Baxter International (BAX) Stock AnalysisBeanvest describes Baxter as an average‑quality medtech reshaped by the 2025 kidney‑care divestiture, arguing that switching‑cost and scale advantages in infusion systems and sterile solutions support an only moderate moat while recent hurricane damage at North Cove, Novum IQ recall issues, high leverage and thin trailing free cash flow leave the equity dependent on sustained FCF improvement and product‑quality stabilization before rerating.